Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen (FATI-01)

This study is ongoing, but not recruiting participants.
European and Developing Countries Clinical Trials Partnership (EDCTP)
German Federal Ministry of Education and Research
National Institute for Medical Research, Tanzania
Treichville Academic hospital center, Division of infectious and tropical diseases (SMIT)
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Kumasi Centre for Collaborative Research (KCCR)
Bernhard Nocht Institute for Tropical Medicine
Pharmaceutical Company (Chiracon GmbH)
Pharmaceutical Company (STADA Vietnam Joint Venture Co. Ltd.)
Information provided by (Responsible Party):
Michael Hoelscher, Ludwig-Maximilians - University of Munich Identifier:
First received: October 25, 2012
Last updated: September 15, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)